ARRIVE, CONSORT, and Equivalent Reporting Guidelines for Biochemistry Studies

ARRIVE, CONSORT, and biochemistry-specific reporting guidelines address a shared problem. Incomplete methods, undocumented reagent variability, and missing analytical decisions prevent readers from judging or repeating an experiment. Their practical value lies in translating reporting requirements into records made at the bench, while the information still exists. A study becomes ready for scrutiny through its experimental workflow.

Why biochemistry has a reporting problem that guidelines were designed to fix

An unrecorded reagent lot can undermine an otherwise carefully described biochemical experiment. Biological reagents vary between lots, so a comparison across experiments or laboratories depends on knowing which material was used and how its performance was assessed. When reagent identity is incomplete, readers cannot establish whether an apparent difference reflects the experimental condition or a change in the material used to test it. Inadequate reagent validation compounds the uncertainty.

A quantitative assay requires enough detail to reconstruct both the experiment and the treatment of its outputs, yet vague descriptions of randomization or blinding prevent readers from assessing bias. An undisclosed analysis plan also leaves selective outcome reporting difficult to detect. These failures intersect in bench biochemistry, where variable biological materials feed into precisely controlled procedures and quantitative comparisons. Reporting guidelines are an institutional response to that combination, rather than an administrative layer unrelated to experimental quality.

What CONSORT 2025 actually requires, and why the update matters beyond clinical trials

CONSORT 2025 provides a current benchmark for transparent reporting of randomized trials. Its April 2025 revision was the first comprehensive update in fifteen years and appeared simultaneously in The BMJ, JAMA, The Lancet, Nature Medicine, and PLOS Medicine. An international Delphi survey and a formal expert consensus meeting informed the revision. The resulting 30-item checklist added seven items, changed three, dropped one, and brought in several extensions. These changes target gaps in published reporting.

The checklist asks how the intervention and comparator were actually administered, including associated care, rather than accepting a description of what investigators intended to administer. The bench analogue is direct. A reaction must be described through what was added and under what conditions. A dose-response assay or protein expression comparison remains outside the scope of clinical trials, but it too calls for a record of what was planned and what was done.

CONSORT now requires a specific statement explaining where and how data, statistical code, and supporting materials can be accessed. “Data available on reasonable request” no longer satisfies the requirement. The revision also makes standardized harms reporting mandatory and adds patient and public involvement, which has no direct bench analogue. CONSORT is explicitly a living document linked to a shared portal with SPIRIT 2025, its companion guideline for trial protocols.

How ARRIVE 2.0 applies when biochemical studies involve in vivo animal work

ARRIVE 2.0 applies when live animals are part of biochemical research. That includes studies validating protein function, measuring enzyme activity in vivo, or generating tissue for downstream biochemical analysis. A detailed description of the downstream assay cannot replace information about the design and conduct of the animal work that supplied its material.

ARRIVE was revised in 2020 and is maintained by the NC3Rs. It separates a 10-item Essential 10, the minimum information needed to assess reliability, from an 11-item Recommended Set providing fuller methodological and contextual detail. For biochemists, the essential requirements include groups and controls, the experimental unit, sample size justification, randomization and allocation concealment, and blinding during measurement. Procedures must explain what was done, how, when, where, and why the method was chosen. Results also need a measure of precision alongside a p-value.

The Recommended Set also asks for details on housing and husbandry, protocol registration, and data access. Those details connect the animal experiment to the conditions under which its biochemical outputs were obtained. A study can pass IACUC review without supplying the information needed to satisfy the Essential 10 because ethical review and reporting assessment are separate processes. Despite broad journal endorsement, anticipated improvements in reporting have not been achieved consistently, making active implementation more consequential than a journal's statement of support.

Domain-specific extensions that address biochemistry workflows more directly than the top-level guidelines

MIQE 2.0 was published in Clinical Chemistry in 2025, building on the original 2009 guidance through an international consortium spanning molecular biology, clinical diagnostics, statistics, regulatory science, and bioinformatics. It requires the reagent manufacturer, catalog number, and batch number, along with assay context sequences when details of the component reagents are otherwise unavailable. Those identifiers make reagent sourcing traceable.

Minimum Information About a Proteomics Experiment, or MIAPE, addresses the proteomics interface. The HUPO Proteomics Standards Initiative maintains guidance specifying the appropriate detail for the components of a proteomics experiment. Metadata are central to that task. When annotation is too sparse and data-sharing protocols are missing, results cannot be reused across studies, even if the original report gives a broad account of how the experiment was done.

STROBE-MetEpi extends the observational study framework to metabolomic epidemiology. It asks for enough detail to repeat the analytical methods, including the instrument name, version, and software version. Across these frameworks, the common requirement is specificity at the point where an experimental or analytical choice can affect reproduction of the work. As extensions are still being developed, researchers in related subdisciplines should check for guidance on their methods, since a top-level checklist may leave out details they need.

Where guidelines have failed to change practice, and why the gap persists

ARRIVE's developers acknowledge that adoption has not delivered the anticipated improvements in reporting quality. Broad endorsement establishes an expectation, but it does not show that manuscripts contain the required information. Journal enforcement is also inconsistent. Requiring a completed checklist confirms that a form was submitted. The gap is therefore between stated requirements and their implementation.

Timing explains much of that gap. A checklist first consulted at submission cannot recover an unrecorded reagent lot, missing randomization records, or an analysis plan that was never established before data collection. Generic wording creates a further weakness. A response can appear to complete a checklist while omitting the manuscript-specific information that the item was intended to elicit. CONSORT's revision tackled this problem by making checklist items that require more than copy-pasted template language.

The practical response is to use reporting requirements prospectively. This means identifying relevant requirements before the decisions they document have passed. The most difficult gaps to repair are often the earliest omissions. Reagent identity, allocation decisions, and a pre-specified analysis approach belong in the experimental record from the outset. In a biochemistry workflow, prospective use begins by attaching those requirements to the moments when materials are selected, reactions are assembled, and outcomes are defined.

Mapping guideline requirements onto the specific documentation decisions biochemists make at the bench

Cell-free protein synthesis provides a concrete example of that approach. For each CFPS experiment, record the manufacturer, catalog number, and lot number of every reagent at the time of use. Lysate activity varies between lots and directly affects protein yield and assay outcomes, so an undocumented lot change introduces an uncontrolled variable into comparisons. QC data for each lot help show how steady its performance is. When those data come with a production run, readers can see more than which reagent was used.

Formulation documentation adds a different kind of interpretability. A publicly documented composition allows readers to understand which variables are present, while an undisclosed formulation restricts troubleshooting and replication. These are distinct documentation needs. Lot records show which material was used, QC data show how it performed in tests, and formulation records show what it contains. Together, they support the reagent traceability emphasized by molecular quantification and proteomics guidance without making a methods section depend on a reagent's category name.

Procedure records must then describe how those materials were used. For CFPS, document reaction volume, template concentration, incubation time and temperature, energy source composition, and additives as the experiment is performed. “Standard CFPS conditions” cannot substitute for those details. In automated or plate-based work, the record also needs the robot model, software version, pipetting parameters, and plate format. This follows how CONSORT asks researchers to record intervention delivery and ARRIVE asks them to record experimental procedures, though ARRIVE formally applies only to the animal part of a study.

For a CFPS protein variant screen, define the primary outcome and the activity threshold or fitness criterion before examining the distribution of results. If the analysis plan is not formally registered, document it in the lab notebook or data management plan at study outset, and explain subsequent deviations in the manuscript. Report precision as well as performance. Confidence intervals, standard errors, or equivalent measures give context that a p-value or fold-change alone does not, while the spread across a high-throughput screening plate complements the result for the best-performing variant. The same reporting principle applies to gel quantification, ELISA readouts, activity assays, and yield measurements.

Building a submission-ready reporting practice from guideline requirements

Begin by selecting guidance for the study design and its component methods through the EQUATOR Network. CONSORT applies to randomized trials, ARRIVE to live-animal work, MIQE to quantitative molecular assays, MIAPE to proteomics-level reporting, and STROBE or its extensions to observational designs. A study may need several frameworks. Research involving animal work to prepare mouse liver lysate for CFPS, for example, requires reporting of that animal component as well as the applicable downstream quantification methods. Identifying those layers at design stage prevents one well-documented component from obscuring another.

Build the recurring requirements into the bench record. A reagent log or a field in the electronic lab notebook can hold lot numbers from each experiment, and instrument models, software versions, and liquid handling parameters can be recorded when they are used. QC data published by the manufacturer make it easier to document lot performance, but the experiment's record must still say which lot was used. Timing makes this practice achievable. It replaces later reconstruction with records made while the materials, settings, and decisions are available.

At manuscript preparation, work through the applicable checklists while drafting the methods. Trial reports under CONSORT also need a specific data-sharing statement that gives the repository, access conditions, and timeline and is developed along with the methods, before the last minute. Check its shared portal for updates if substantial time has passed since study design. The completed manuscript can then draw on an existing record. Its value extends beyond acceptance to work another laboratory can replicate, evidence a systematic review can use, and results that remain interpretable as methods evolve.